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Background: COPD patients who remain hypercapnic after acute respiratory failure requiring
mechanical ventilation have a poor prognosis. Long-term nocturnal non-invasive ventilation
(NIV) may be beneficial for these patients. We hypothesized that stable patients on long-term
NIV would experience clinical worsening after withdrawal of NIV.
Methods: We included 26 consecutive COPD patients (63 6 years, 58% male, FEV1 31 14% pre-
dicted)who remainedhypercapnic after acute respiratory failure requiringmechanical ventilation.
After a six month run-in period, during which all patients received NIV, they were randomised to
either continue (ventilation group, nZ 13) or to stop NIV (withdrawal group, nZ 13). The primary
endpoint was time to clinical worsening defined as an escalation of mechanical ventilation.
Results: All patients remained stableduring the run-in period. After randomisation thewithdrawal
group had a higher probability of clinical worsening compared to the ventilation group
(pZ 0.0018). After 12 months, ten patients (77%) in the withdrawal group, but only two patients
(15%) in the ventilation group, experienced clinical worsening (pZ 0.0048). Six-minute walking
distance increased in the ventilation group.
Conclusion: COPD patients who remain hypercapnic after acute respiratory failure requiring
mechanical ventilation may benefit from long-term NIV.
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428 G.-C. Funk et al.Introduction Conduct of the trialThe benefit of non-invasive ventilation (NIV) for the treat-
ment of acute respiratory failure in COPD has been well
documented in multiple studies and meta analyses; 1
however, whether NIV is beneficial for COPD patients with
chronic respiratory failure is less clear.2 To date, one
sufficiently powered study suggests that NIV conveys
a small survival benefit. There are conflicting results,
however, about the effects of NIV on clinical stability as
assessed by hospitalisation rate.3e6 Thus, it remains
unclear which subgroup of stable COPD patients may
benefit from NIV.
COPD patients who have required mechanical ventila-
tion for an episode of acute respiratory failure have
a very poor prognosis.7,8 In addition, those COPD patients
who are hypercapnic on hospital discharge have a higher
mortality rate than those who are normocapnic. There-
fore, we hypothesised that NIV would be beneficial for
COPD patients who remain hypercapnic after an episode
of acute respiratory failure requiring mechanical venti-
lation. If this hypothesis were true, the withdrawal of
long-term nocturnal NIV should induce clinical worsening
in stable COPD patients. Hence, the objective of this
study was to determine whether the withdrawal of long-
term NIV causes clinical worsening in stable COPD
patients who remained hypercapnic after an episode of
acute respiratory failure requiring mechanical
ventilation.
Methods
This trial was approved by the Institutional ethics
committee, and written informed consent was obtained
from all participants.
Participants
The study was conducted in the Department of Respiratory
and Critical Care Medicine at the Otto Wagner Hospital,
Pulmonary Centre, Vienna. Patients were recruited on the
respiratory care unit, which cares for patients with acute
and chronic respiratory failure and patients with prolonged
weaning, including those who require long-term invasive or
non-invasive ventilation. Inclusion criteria for the study
were as follows: (1) COPD according to standard criteria; 9
(2) requiring invasive or non-invasive mechanical ventila-
tion during an episode of acute respiratory failure due to
exacerbation of COPD, according to standard criteria; 9 (3)
clinically stable and hypercapnic (PaCO2 > 45 mmHg
measured immediately after awakening from a night
without mechanical ventilation) after six months on home
nocturnal NIV and (4) patient approval.
Exclusion criteria were (1) severe psychiatric disorder
likely to impair the ability to comply with NIV; (2) other
severe pulmonary diseases except COPD; (3) other severe
non-pulmonary disease limiting prognosis (e.g., metastatic
cancer, congestive heart failure, liver cirrhosis); (4) non-
compliance with NIV; (5) women of childbearing age and (6)
polysomnographic evidence of sleep apnoea (>15 apnoeas
plus hypopnoeas per hour of sleep).Treatment of acute respiratory failure
Acute respiratory failure was treated according to inter-
national standards.9 Mechanical ventilation was applied
non-invasively using individual interfaces and/or invasively
via an endotracheal tube or tracheal cannuala. NIV was
used as the preferred primary method and was also used to
facilitate weaning.10 After primary stabilisation from acute
respiratory failure and upon enrolment, all patients were
free of an invasive airway.
Initiation of NIV
COPD patients in our department are routinely evaluated for
nocturnal NIV if they remain hypercapnic with symptoms of
chronic respiratory failure after an episode of acute respi-
ratory failure requiring mechanical ventilation. Evaluation
was started before discharge from the ICU or immediately
after transfer to regular wards. Patients who started
nocturnal NIV were transferred to the respiratory care unit
for three to five days and trained to use NIV according to
a standardised protocol. Various types of patient-triggered
bi-level positive pressure ventilators were used. The level of
inspiratory aid was increasingly raised from 10 cm H20 to
approximately 20 cm H20, with a level of expiratory positive
airway pressure around 5 cm H20. The inspiratory time was
limited to a maximum of 1.3 s to avoid leak-induced prolon-
gation of inspiration. The fraction of inspired oxygen was
adjusted to correct for nocturnal hypoxaemia, as ascer-
tained by nocturnal oximetry. The choice of nasal versus full
face mask and humidification was determined by the respi-
ratory physiotherapist to maximise patient comfort. NIV
efficiency was ascertained by nocturnal oximetry and serial
arterial blood gases.
Six month run-in phase
All patients meeting the study criteria who were discharged
from the respiratory care unit with home NIV were enrolled
in the run-in phase. At that time, patients were informed
about the trial, and informed consent was obtained. The
run-in phase lasted six months, during which patients
needed to remain stable on home nocturnal NIV. After
three months, they were re-admitted to the respiratory
care unit for one night for re-assessment of the inclusion
and exclusion criteria. Therefore, patients were excluded if
they had become normocapnic or had stopped home NIV for
any reason. Appropriate compliance with NIV was assured
using the hour meter values on the home ventilator.
Optimal medical treatment according to the GOLD guide-
lines was ascertained in all patients.9
Randomisation
After the six months run-in phase, patients were re-
admitted to the respiratory care unit and randomly
assigned with the use of a block randomisation scheme to
either stop NIV (withdrawal group) or continue NIV (venti-
lation group). Randomisation was done with equal
Figure 1 Study flow chart of the NIVEX trial. NIV, non-inva-
sive ventilation.
Long-term non-invasive ventilation 429allocation to groups. Patients from whom NIV was with-
drawn were informed that they had the option to volun-
tarily resume NIV if dyspnoea increased severely.
Primary outcome measure
The primary endpoint was time to clinical worsening
defined as an escalation of mechanical ventilation. In both
groups, escalation of mechanical ventilation was defined as
intensive care unit (ICU) admission for treatment of acute-
on-chronic respiratory failure. In the withdrawal group,
escalation of mechanical ventilation additionally comprised
(1) voluntary resumption of NIV due to severe dyspnoea or
(2) re-institution of NIV due to progressive hypercapnia
defined by an increase of PaCO2  10% compared to the
prior visit. These two endpoints were included for ethical
concerns, as a successfully established therapy was to be
withdrawn from stable patients. It was felt that they must
have access to NIV in case their subjective shortness of
breath became unbearable. On the other hand, an increase
in PaCO2 at a control visit was used as an objective criterion
to resume NIV to detect those patients who were about to
develop acute-on-chronic respiratory failure in a timely
manner. These safety considerations were confirmed by the
Institutional ethics committee.
Follow-up and secondary outcome measures
Patients were followed for twelve months with control visits
every three months. At each control visit, patients were
admitted to the respiratory care unit for two nights. Irre-
spective of group allocation, all patients slept one night
without NIV. Supine resting arterial blood gases were taken
prior to sleep and on first waking on both occasions with the
patient breathing oxygen via nasal cannulae at their
prescribed flow rate. Polysomnography was repeated during
the second night. To obtain exercise PaCO2, a cycle ergom-
eter test was performed using a 2-min incremental cycle
exercise protocol. Patients started with a 2-min period of
unloaded pedalling at 60 cycles/min, followed by 20-Watt
increments/2 min. Arterial blood gases were collected after
120 s of cycling at 20Watts. Functional exercise capacity was
additionally assessed using the 6-min walking distance.11
Standard spirometry was recorded at every visit according
to the ATS/ERS recommendations,12 using a standard
pulmonary function test unit (SensorMedics Vmax 22, Viasys
Healthcare). Blood gases were determined using the AVL
Compact 3 Blood Gas Analyzer (Roche Diagnostics, Graz,
Austria). Maximum inspiratory pressure was measured using
an esophageal balloon catheter (Bicore Monitoring Systems,
Irvine, CA, USA). Disease-specific quality of life was assessed
by the Saint Georges Respiratory Questionnaire (SGRQ,
0 pointsZ best result, 100 pointsZ worst result).13
Patientswithworsening symptoms,bloodgases and/or lung
function were treated according the GOLD guidelines.9 Inci-
dences of antibiotic and oral steroid therapy were recorded.
Sample size calculation
We estimated that a clinical relevant difference in median
time to clinical worsening would be 100 days. From ourclinical experience we estimated the time to clinical
worsening to be 60 days in the withdrawal group and hence
160 days in the ventilation group. Based on this difference,
an alpha error probability of 0.05 and a beta error proba-
bility of 0.9, the necessary total sample size was deter-
mined to be 26. Sample size was calculated using ‘PS Power
and Sample Size Calculations Version 2.1.30’14 and
confirmed using STATA version 8. Interim analyses and
stopping rules were not used in the trial.
Statistical methods
Statistical analyses were performed using SPSS version 15.0
software (SPSS Inc., Chicago, Illinois). The ManneWhitney U
test was used for comparison of continuous variables.
Fisher’s exact test was used to compare categorical vari-
ables between the two groups. Time to clinical worsening
was depicted using a KaplaneMeier plot, and the log-rank
test was used to compare the two groups. To compare serial
PaCO2 measurements between the two groups, we used
a generalised estimating equation assuming an exchange-
able correlation matrix for repeated observations within
one patient.15 To compare the number of days using anti-
biotics or steroids between the two groups, we used
a generalised estimating equation assuming an exchange-
able correlation matrix for repeated observations within
one patient.15 Data are presented as mean  SD, median
(1ste3rd quartiles), or a proportion as appropriate.
Differences between groups are reported as median or
mean and 95% confidence interval. A two-sided
p-value < 0.05 was considered statistically significant.
Table 1 Demographic and clinical characteristics after the first acute-on-chronic respiratory failure.
Ventilation group Withdrawal group
Patients studied N Z 13 N Z 13
Male sex, n (%) 7 (54%) 8 (62%)
Age, years 62  6 65  6
Body mass index, kg/m2 24.2  4.3 27.0  5.4
Spirometry
FEV1, litres 0.75  0.34 0.82  0.32
FEV1% predicted 31  17 30  12
FVC, litres 2.14  0.57 2.08  0.81
FEV1/FVC 38  11 43  11
GOLD stage of COPD, n(%)
II 2 (15%) 1 (8%)
III 1 (8%) 2 (15%)
IV 10 (77%) 10 (77%)
Blood gas on ICU admission
PaCO2, mmHg 92  19 95  26
pH 7.23  0.08 7.25  0.08
PaO2/FiO2 ratio 209  82 209  58
Maximum inspiratory pressure, cmH2O 72  19 74  21
Long-term oxygen therapy at randomisation 9 (69%) 9 (69%)
Six-minute walking distance, meters 288  102 319  163
SGRQ*, median 1st to 3rd quartiles 60 (50e71) 59 (52e69)
Co-morbidities
Coronary artery disease 0 0
Congestive heart failure 0 1 (8%)
Chronic renal failure 0 0
Diabetes 2 (15%) 3 (23%)
History of stroke 0 0
Peripheral arterial disease 0 1 (8%)
Arterial hypertension 5 (39%) 9 (63%)
Therapy
Inhaled short-acting beta agonists 3 (23%) 3 (23%)
Inhaled long-acting beta agonists 11 (85%) 8 (62%)
Inhaled short-acting muscarinic antagonist 3 (23%) 1 (8%)
Inhaled long-acting muscarinic antagonist 11 (85%) 8 (62%)
Inhaled corticosteroid 11 (85%) 8 (62%)
Oral corticosteroid 2 (15%) 0 (0%)
Calcium channel blocker 1 (8%) 2 (15%)
Angiotensin-converting enzyme inhibitor 6 (46%) 4 (31%)
Oral theophylline 2 (15%) 4 (31%)
Beta blocker 1 (8%) 1 (8%)
Diuretic 2 (15%) 3 (23%)
Other medication 5 (38%) 2 (15%)
Data are given as mean  standard deviation unless otherwise indicated. * SGRQ, Saint George Respiratory Questionnaire.
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All 998 patients treated at the respiratory care unit from
April 1, 2003, to February 28, 2007, were screened for
eligibility; 38 patients (4%) met the study criteria and
were enrolled in the run-in phase. During the run-in
phase, 12 patients were excluded for various reasons
(Fig. 1). After the run-in phase, 26 patients still fulfilled
the study criteria and were randomised. Baseline demo-
graphic and clinical characteristics of the withdrawal
group and of the ventilation group are shown in Table 1.
With respect to co-morbidities arterial hypertension ten-
ded to be more common in the withdrawal group
(p Z 0.11).Enrolment was stopped after 26 patients had been
randomised. All randomised patients remained in their
allocated group and could be followed over the subsequent
12 months.
During the 12-month follow-up period, the withdrawal
group had a significantly higher probability of clinical
worsening compared to the ventilation group (p Z 0.0018)
(Fig. 2). Mean time to clinical worsening in the withdrawal
group and in the ventilation group was 162  40 days and
391  36 days, respectively.
At the end of the 12-month follow-up period, ten
patients (77%) in the withdrawal group, but only two
patients (15%) in the ventilation group, experienced clinical
worsening (p Z 0.0048). In the withdrawal group, three
Figure 2 KaplaneMeier plot of the probability of clinical
worsening in patients after withdrawal (withdrawal group) or
continuation of NIV (ventilation group). Log-rank test statistic:
p Z 0.0018.
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respiratory failure; four patients needed to resume NIV due
to severe dyspnoea, and in three patients NIV was recom-
menced due to progressive hypercapnia. In the ventilation
group, two patients were admitted to the ICU for acute-on-
chronic respiratory failure.
Three months after randomisation, 6-min walking
distance increased by 43  79% in the ventilation group but
decreased by 11  25% in the withdrawal group, pZ 0.0425
(Fig. 3). Three months after randomisation, the SGRQ total
score did not differ between the ventilation group
[57 (44e67)] and the withdrawal group [53 (45e63); median
(1ste3rd quartile), p Z 0.80).
Withdrawal of NIV had no significant effect on follow-up
on daytime resting PaCO2 (Table 2). However, in the with-
drawal group resting daytime pH was slightly lower (Table 2
and Fig. 4). At randomisation, PaCO2 during exercise was
stable in both groups; the median (1ste3rd quartile) change
in PaCO2 between rest and 20 Watts was 0.4 (3.3 to 4.0)
mmHg in the withdrawal group and 1.0 (3.0 to 4.3) mmHg
in the ventilation group (p Z 0.60 for between groupFigure 3 Six-minute walking distance three months after
randomisation to withdrawal (withdrawal group, n Z 10) or
continuation of NIV (ventilation group, nZ 12). ManneWhitney
U test statistic: p Z 0.0425.comparison). Three months after randomisation, the
median (1st to 3rd quartile) change in PaCO2 showed
a trend toward an increase in the withdrawal group [3.7
(0.3 to 7.5)] but remained unchanged in the ventilation
group [0.9 (3.6 to 3.0)]. This difference, however, did
not reach statistical significance (p Z 0.0825 for between
group comparison).
Daytime resting PaO2, litres of oxygen administered,
arterial bicarbonate and FEV1%predicted did not differ
between the two groups during follow-up (Table 2). At all
follow-up visits, sleep studies performed in all patients did
not show evidence of newly acquired obstructive sleep
apnoea.
The incidence density rate of antibiotic therapy due to
exacerbation was 0 (0e1.02) and 0.23 (0e2.48) days per
100 patient days in the withdrawal group and in the
ventilation group respectively, p Z 0.35. The incidence
density rate of oral steroid therapy due to exacerbation was
0 (0e0) and 0 (0e1.79) days per 100 patient days in the
withdrawal group and in the ventilation group respectively,
p Z 0.59; data are medians and 1st to 3rd quartiles.Discussion
We show that the withdrawal of NIV causes clinical wors-
ening in COPD patients with chronic hypercapnic respira-
tory failure. Patients who had previously required
mechanical ventilation for treatment of acute respiratory
failure and who remain hypercapnic thereafter may benefit
from long-term NIV.
The rationale and main novelty of our study were both
the idea that the most severely sick subgroup of COPD
patients is the most likely to benefit from NIV. Therefore,
our study is the first to include only patients who have
already required mechanical ventilation for an episode of
acute respiratory failure. Our positive results confirm the
recent findings of McEvoy et al,4 who showed a small
survival benefit of NIV in stable COPD patients after
adjustment of baseline gas exchange and symptoms. Earlier
studies on this topic were significantly underpowered to
examine mortality.3,5
Our finding of sustained clinical stability due to NIV is in
line with the findings of Casanova et al. who observed
a reduction in the number of hospital admissions after
three months.5 Additionally, Tuggey et al. showed that
domiciliary NIV in COPD patients with recurrent admissions
for acute-on-chronic respiratory failure requiring NIV
reduced hospital admissions.6 In contrast, studies by Clini
et al. and McEvoy et al. showed no reduction in hospital
admission in the NIV group as compared to the group on
long-term oxygen therapy. The clearly positive results of
our study can likely be explained by our selection of
patients with a high probability of recurrent respiratory
failure.
We chose the time to clinical worsening as the primary
endpoint because we considered it to be one of the most
relevant clinical outcome variables in this patient pop-
ulation. Moreover, the statistical analysis of the time to an
outcome is more robust and independent of assumptions
compared to the analysis of repeated outcomes such as
exacerbation rate or hospitalisation rate.16
Table 2 Blood gas data and FEV1 during the course of the study. The p values refer to the between-groups comparisons.
Enrollment Randomization 3 Months 6 Months 9 Months 12 Months p Value
PaCO2, mmHg withdrawal group 56  8 57  11 57  13 56  8 59  11 58  4 0.074
ventilation group 57  13 51  10 53  10 49  12 54  13 50  8
pH withdrawal group 7.39  0.04 7.36  0.04 7.35  0.05 7.36  0.02 7.37  0.05 7.35  0.02 0.019
ventilation group 7.37  0.03 7.39  0.04 7.39  0.05 7.38  0.06 7.39  0.04 7.40  0.05
Bicarbonate,
mmol/L
withdrawal group 33  5 31  4 30  4 31  3 33  5 31  1 0.77
ventilation group 32  5 30  4 31  4 28  6 32  5 30  3
PaO2, mmHg withdrawal group 80  15 77  15 72  16 69  14 75  18 71  19 0.064
ventilation group 76  13 80  22 89  21 76  24 79  20 78  18
oxygen, lit/min withdrawal group 2 (2e3) 2 (1e2) 2 (1e2) 2 (2e2) 3 (2e3) 2 (0e2) 0.25
ventilation group 2 (1e3) 2 (0e3) 1 (0e3) 1 (0e3) 3 (0e4) 2 (0e3)
FEV1%predicted withdrawal group 32  11 31  14 34  11 36  7 32  7 32  5 0.9
ventilation group 32  17 33  15 33  19 32  20 31  16 34  16
Data are given as mean  standard deviation.
432 G.-C. Funk et al.In this trial, by definition the achievable endpoints
depended on the group allocation of the patient: after
withdrawal of NIV, ventilator support could be escalated by
either resumption of NIV or by ICU admission for acute-on-
chronic respiratory failure. In patients who already were on
nocturnal NIV, however, only the latter endpoint was
applicable.
The criterion of a 10% increase in resting morning PaCO2
for re-institution of NIV was arbitrarily chosen after
consultation with various experts in the field. It allows for
larger variations in severely hypercapnic patients but is
very sensitive when hypercapnia is mild. McEvoy et al.
found that PaCO2 remained almost completely unchanged
during one year in stable hypercapnic COPD patients with
our without NIV.2 Therefore the criterion of a 10% increase
of PaCO2 probably represents ventilatory deterioration.
However, the amount of natural fluctuations of PaCO2 is
unpredictable within an individual patient. Therefore it
cannot be excluded that some of the increases of PaCO2
which were regarded as an endpoint were actually due to
the natural variation of alveolar ventilation.
Although dyspnoea is a subjective measure and varies
between patients, we chose to use it as an endpoint, when
it became so severe that the patient deliberately resumed
NIV. NIV is an intervention, which may also bring along
subjective discomfort during sleep. We therefore reasoned,
that voluntary resumption of a potentially disturbing
therapy to alleviate dyspnoea actually represents clinical
worsening and strongly suggests that the patient actually
benefits from NIV.Figure 4 Changes in pH during the run-in phase and after
randomisation to withdrawal (withdrawal group) or continua-
tion of NIV (ventilation group).Our results have some limitations. While basically both
groups were well matched with regard to baseline charac-
teristics arterial hypertension tended to be more common
in the withdrawal group. Since blood pressure was checked
and treated in all patients during all visits and since no
episode of uncontrolled hypertension or heart failure
occurred, this difference is unlikely to be relevant for the
main finding.
The sample size calculation was based on an arbitrary
number of days with clinical stability. Since this specific
subtype of COPD patients after mechanical ventilation due
to acute-on-chronic respiratory failure has not been studied
in a comparable way so far, we were not able to find
a reasonable estimate from the literature. We reasoned
that 100 days spent at home without clinical worsening
would be considered relevant by most patients and the
health care providers.
The exact mechanisms of the physiologic effects of long-
term mechanical ventilation in COPD are unclear.17 NIV has
been shown to reduce the activity of the ventilatory
muscles in many studies;18e24 however, most studies have
failed to show an improvement in maximum inspiratory
force.3,5,22,25e29 It can be speculated that nocturnal NIV
allows maintaining the balance between load and capacity
of the ventilatory pump. The observed trend towards CO2
retention during exercise indicates that ventilatory failure
may be responsible for exercise limitation after withdrawal
of NIV.
The effect of the withdrawal of NIV on self perceived
well-being using the SGRQ could only be assessed until
three months after randomisation. Potential effects on
long-term quality of life, however, could not be analysed
owing to the small remaining sample size after many
patients had experienced endpoints.
Our findings indicate that a very specific patient pop-
ulation benefits from NIV. COPD patients who require
mechanical ventilation due to an exacerbation and
remain hypercapnic thereafter should be evaluated for
this therapy in specialised respiratory care centres.
During this time patients are trained, informed and
motivated, and ventilatory settings are optimised. After
primary initiation of home NIV, patients should have
regular follow-up visits at the hospital every three to six
months. It should be clearly stated, that our findings only
FEV1%predicted Predicted forced expiratory volume in 1 s
FVC Forced vital capacity
PaO2/FiO2 Ratio of the partial pressure of oxygen in arte-
rial blood to fraction of oxygen in inspired air
Long-term non-invasive ventilation 433relate to the most severely ill COPD patients, who have
already survived one episode of acute respiratory failure
requiring mechanical ventilation. It is not suggested that
all COPD patients with stable hypercapnia benefit from
long-term NIV.
Future research should be aimed at early identification
of those patients who are most likely to benefit from NIV.
Candidates may be not only patients who have already
required mechanical ventilation, but also patients who
have been discharged hypercapnic after a severe exacer-
bation.7 Aggravation of hypercapnia during exercise may be
a tool for the identification of patients at risk for acute-on-
chronic ventilatory failure.
In conclusion, discontinuation of NIV causes clinical
worsening in stable COPD patients who remain hypercapnic
after an episode of acute respiratory failure requiring
mechanical ventilation. Therefore, these patients should
be evaluated for NIV in a specialised centre as they may
benefit from long-term NIV.
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